Valuation: Center Laboratories, Inc.

Capitalization 31.06B 991M 835M 761M 726M 1.35B 89.88B 1.4B 8.84B 3.52B 43.24B 3.71B 3.64B 152B P/E ratio 2023
-29.5x
P/E ratio 2024 -28.2x
Enterprise value 35.54B 1.13B 955M 871M 830M 1.54B 103B 1.6B 10.12B 4.02B 49.47B 4.25B 4.16B 174B EV / Sales 2023
23.5x
EV / Sales 2024 22.3x
Free-Float
76.01%
Yield 2023
3.39%
Yield 2024 1.71%
01-13 WuXi XDC Cayman Inc. proposed to acquire 60% stake in BioDlink International Company Limited from a group of shareholders for HKD 1.9 billion. CI
11-11 Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
13/08/25 Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/06/25 Tranche Update on Center Laboratories, Inc.'s Equity Buyback Plan announced on April 9, 2025. CI
08/06/25 Center Laboratories, Inc.'s Equity Buyback announced on April 9, 2025, has expired with 9,909,000 shares, representing 1.38% for TWD 383.08 million. CI
11/05/25 Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
07/05/25 Medeon Biodesign, Inc. cancelled the transaction announced on February 29, 2024 CI
09/04/25 Center Laboratories, Inc. announces an Equity Buyback for 20,000,000 shares, representing 2.76% for TWD 9,141.18 million. CI
08/04/25 Center Laboratories, Inc. authorizes a Buyback Plan. CI
23/03/25 Guangzhou Hybot Technology Co., Ltd. announced that it has received CNY 450 million in funding from CS Capital Co., Ltd., Beijing Taiji Huaqing Peicheng Software Technology Co., Ltd., Hydrogenics Corporation, Guangzhou Shuimu Qingyun Equity Investment Partnership Enterprise (Limited Partnership), Beijing Shunyuan Changxin Consulting Management Partnership Enterprise (Limited Partnership, Hainan Yide Investment Partnership Enterprise (Limited Partnership), Center Laboratories, Inc. CI
14/03/25 Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
11/03/25 Center Laboratories, Inc. Proposes Dividend for Year Ended December 31, 2024 CI
10/03/25 Center Laboratories, Inc. announced a financing transaction CI
1 day+0.76%
1 week+1.52%
Current month-0.74%
1 month-4.31%
3 months+6.24%
6 months+11.78%
Current year-3.85%
1 week 39.3
Extreme 39.3
40.5
1 month 38.35
Extreme 38.35
44.3
Current year 38.35
Extreme 38.35
44.55
1 year 29.12
Extreme 29.1236
44.55
3 years 29.12
Extreme 29.1236
58.79
5 years 29.12
Extreme 29.1236
58.79
10 years 20.99
Extreme 20.9884
64.21
Manager TitleAgeSince
Chief Executive Officer - 02/08/1998
Director of Finance/CFO - 07/12/2022
Chief Tech/Sci/R&D Officer - 30/06/1983
Director TitleAgeSince
Chairman - 29/11/2022
Director/Board Member 61 13/06/2010
Director/Board Member - 13/06/2010
Change 5d. change 1-year change 3-years change Capi.($)
+0.76%+1.52%+2.38%-2.95% 951M
+0.17%-1.72%+23.18%+210.44% 929B
-0.45%+1.44%+55.91%+52.76% 587B
+1.76%+3.61%+20.03%+53.25% 409B
+0.39%+1.40%+22.72%+30.42% 374B
+0.28%+7.49%+29.48%+31.05% 320B
+1.05%+5.42%+32.60%+56.70% 311B
+1.82%-0.43%+46.26%+12.75% 301B
-0.95%+4.11%-44.82%-37.79% 219B
+0.82%-3.94%+26.80%+53.79% 199B
Average +0.57%+1.76%+21.45%+46.04% 364.97B
Weighted average by Cap. +0.46%+1.36%+27.41%+80.40%

Financials

2023 2024
Net sales 1.39B 44.46M 37.47M 34.16M 32.58M 60.53M 4.03B 62.88M 397M 158M 1.94B 167M 163M 6.83B 1.62B 51.6M 43.49M 39.64M 37.81M 70.26M 4.68B 72.98M 461M 183M 2.25B 194M 190M 7.92B
Net income -995M -31.75M -26.75M -24.39M -23.26M -43.23M -2.88B -44.9M -283M -113M -1.39B -119M -117M -4.87B -1.1B -35.2M -29.66M -27.04M -25.79M -47.93M -3.19B -49.79M -314M -125M -1.54B -132M -129M -5.4B
Net Debt 2.2B 70.09M 59.06M 53.84M 51.35M 95.42M 6.36B 99.12M 626M 249M 3.06B 263M 257M 10.76B 4.48B 143M 120M 110M 105M 195M 12.97B 202M 1.28B 507M 6.24B 536M 525M 21.93B
Logo Center Laboratories, Inc.
Center Laboratories Inc is a Taiwan-based company engaged in the development of pharmaceutical products. The Company's products mainly focus on internal liquids, including syrups, suspensions, liquids and other dosage forms. Pharmacological classifications include respiratory tract therapeutics such as cough suppressants, sputum expectorants, asthma medications, and runny nose relief, while antipyretic and analgesic medications and gastrointestinal medications are also in great demand, and a variety of internal liquids and lozenges for the treatment of central nervous system (CNS) such as epilepsy, dysphoria, dementia, and Parkinson's disease have already been introduced into the market. The Company is a specialized manufacturer of internal liquid.
Employees
-
Date Price Change Volume
11/02/26 40.00 NT$ +0.76% 1,106,263
10/02/26 39.70 NT$ +1.66% 1,209,292